P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-Loperamide

Permeability-glycoprotein (P-gp), an efflux transporter in several organs, acts at the blood–brain barrier to protect the brain from exogenous toxins. P-gp almost completely blocks brain entry of the PET radiotracer 11C-N-desmethyl-loperamide (11C-dLop). We examined the ability of 11C-dLop to quantify P-gp function in humans after increasing doses of tariquidar, an inhibitor of P-gp. Methods: Seventeen healthy volunteers had a total of 23 PET scans with 11C-dLop at baseline and after increasing doses of tariquidar (2, 4, and 6 mg/kg intravenously). A subset of subjects received PET with 15O-H2O to measure cerebral blood flow. Brain uptake of 11C-dLop was quantified in 2 ways. Without blood data, uptake was measured as area under the time–activity curve in the brain from 10 to 30 min (AUC10–30). With arterial blood data, brain uptake was quantified with compartmental modeling to estimate the rates of entry into (K1) and efflux from (k2) the brain. Results: Brain uptake of radioactivity was negligible at baseline and increased only slightly (∼30%) after 2 mg of tariquidar per kilogram. In contrast, 4 and 6 mg of tariquidar per kilogram increased brain uptake 2- and 4-fold, respectively. Greater brain uptake reflected greater brain entry (K1), because efflux (k2) and cerebral blood flow did not differ between tariquidar-treated and untreated subjects. In the subjects who received the highest dose of tariquidar (and had the highest brain uptake), regional values of K1 correlated linearly with absolute cerebral blood flow, consistent with high single-pass extraction of 11C-dLop. AUC10–30 correlated linearly with K1. Conclusion: P-gp function at the blood–brain barrier in humans can be quantified using PET and 11C-dLop. A simple measure of brain uptake (AUC10–30) may be used as a surrogate of the fully quantified rate constant for brain entry (K1) and thereby avoid arterial sampling. However, to dissect the function of P-gp itself, both brain uptake and the influx rate constant must be corrected for radiotracer delivery (blood flow).

[1]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[2]  Shu-Feng Zhou,et al.  An update on clinical drug interactions with the herbal antidepressant St. John's wort. , 2008, Current drug metabolism.

[3]  P Bevan,et al.  Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Jennifer L. Donovan,et al.  Aripiprazole brain concentration is altered in P-glycoprotein deficient mice , 2009, Schizophrenia Research.

[5]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[6]  Roman Rouzier,et al.  Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma , 2005, Cancer.

[7]  T. Fojo,et al.  A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine , 2009, Clinical Cancer Research.

[8]  M. Raichle,et al.  Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Yuichi Sugiyama,et al.  Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Christopher M Waters,et al.  Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. , 2008, American journal of physiology. Cell physiology.

[11]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[12]  Wolfgang Löscher,et al.  Several major antiepileptic drugs are substrates for human P-glycoprotein , 2008, Neuropharmacology.

[13]  Richard E Carson,et al.  Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  P. Herscovitch,et al.  P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using 11C-N-Desmethyl-Loperamide in Monkeys , 2008, Journal of Nuclear Medicine.

[15]  R. Kramer,et al.  Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.

[16]  M. Fromm,et al.  Importance of P-glycoprotein at blood-tissue barriers. , 2004, Trends in pharmacological sciences.

[17]  Jeih-San Liow,et al.  N-desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier , 2010, Drug Metabolism and Disposition.

[18]  M. Hall,et al.  Imaging the Function of P‐Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications , 2009, Clinical pharmacology and therapeutics.

[19]  Michael J. Welch,et al.  Imaging Multidrug Resistance P-glycoprotein Transport Function Using MicroPET with Technetium-94m-Sestamibi , 2005, Molecular imaging.

[20]  Jeih-San Liow,et al.  Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein , 2009, Journal of Nuclear Medicine.

[21]  Jeih-San Liow,et al.  11C-Loperamide and Its N-Desmethyl Radiometabolite Are Avid Substrates for Brain Permeability-Glycoprotein Efflux , 2008, Journal of Nuclear Medicine.

[22]  Jeih-San Liow,et al.  Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. , 2008, Journal of medicinal chemistry.

[23]  Gary M Pollack,et al.  Modulation of P-glycoprotein Transport Activity in the Mouse Blood-Brain Barrier by Rifampin , 2003, Journal of Pharmacology and Experimental Therapeutics.

[24]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  Krzysztof Jamroziak,et al.  Pharmacogenomics of MDR1/ABCB1 Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies , 2004, Hematology.

[26]  R. Béliveau,et al.  Cellular localization of P-glycoprotein in brain versus gonadal capillaries. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.